Recco Bio-B (02179) is forecasting that the loss due to shareholders in the medium term was 2.01-222 million yuan, narrowing by about 34.71% to 40.93% year-on-year

According to the Zhitong Finance App, Ricoh Biotech (02179) issued an announcement. It is expected to obtain revenue of 400-54,000 yuan from January 1, 2026 to June 30, 2026, a year-on-year decrease of about 99.50% to 99.63%; parent company owners should account for losses of 2.01-222 million yuan, narrowing by about 34.71% to 40.93% year-on-year.

Losses narrowed year-on-year during the reporting period, mainly due to the completion of the main work and large-scale investment phase of clinical trials of the company's core products as planned. As the focus of some projects shifted to registration verification and commercialization preparations, R&D investment declined accordingly. At the same time, due to the fact that the company confirmed an amount of external intellectual property licensing revenue in the same period last year, similar licensing business was being promoted during the reporting period but had not yet met the revenue recognition conditions, and revenue declined year-on-year during the reporting period. Overall, losses are narrowing, but there is still room for further improvement.